Palifermin for the protection and regeneration of epithelial tissues following injury: New findings in basic research and pre-clinical models

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 9, 2013, Pages 1065-1087

  Finch, Paul W ^a   Mark Cross, Lawrence J ^b   Mcauley, Daniel F ^b   Farrell, Catherine L ^c  

^a The Queen's University of Belfast ^*

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Epistem Ltd   (United Kingdom)

Author keywords

Cytoprotection; Epithelial repair; FGFR2b; GVHD; Immune reconstitution; KGF; Mucositis; Palifermin; Pericardial adhesions; Pre synaptic organizing molecules; Pulmonary injury; Regeneration; Urothelium; Wound healing

Indexed keywords

KERATINOCYTE GROWTH FACTOR; PALIFERMIN; PROTECTIVE AGENT;

ANIMAL; ARTICLE; CELL PROTECTION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; EPITHELIAL REPAIR; EPITHELIUM; FGFR2B; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RECONSTITUTION; INJURY; KGF; LUNG INJURY; MUCOSA INFLAMMATION; PATHOLOGY; PERICARDIAL ADHESIONS; PRE-SYNAPTIC ORGANIZING MOLECULES; REGENERATION; UROTHELIUM; WOUND HEALING;

CYTOPROTECTION; EPITHELIAL REPAIR; FGFR2B; GVHD; IMMUNE RECONSTITUTION; KGF; MUCOSITIS; PALIFERMIN; PERICARDIAL ADHESIONS; PRE-SYNAPTIC ORGANIZING MOLECULES; PULMONARY INJURY; REGENERATION; UROTHELIUM; WOUND HEALING;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPITHELIUM; FIBROBLAST GROWTH FACTOR 7; HUMANS; PROTECTIVE AGENTS; REGENERATION;

EID: 84884734549     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12091     Document Type: Article

References (299)

1. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011; 149: 121-30.
2. Mohammadi M, Olsen SK, Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin Struct Biol. 2005; 15: 506-16.
3. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001; 2: REVIEWS3005.
4. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002; 16: 1446-65.
5. Gilbert E, Del Gatto F, Champion-Arnaud P, et al. Control of BEK and K-SAM splice sites in alternative splicing of the fibroblast growth factor receptor 2 pre-mRNA. Mol Cell Biol. 1993; 13: 5461-8.
6. Orr-Urtreger A, Bedford MT, Burakova T, et al. Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol. 1993; 158: 475-86.
7. Yan G, Fukabori Y, McBride G, et al. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol. 1993; 13: 4513-22.
8. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010; 342: 1-11.
9. Schoorlemmer J, Goldfarb M. Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase. J Biol Chem. 2002; 277: 49111-9.
10. Goldfarb M, Schoorlemmer J, Williams A, et al. Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron. 2007; 55: 449-63.
11. Finch PW, Rubin JS, Miki T, et al. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science. 1989; 245: 752-5.
12. Rubin JS, Osada H, Finch PW, et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA. 1989; 86: 802-6.
13. Ohuchi H, Hori Y, Yamasaki M, et al. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun. 2000; 277: 643-9.
14. Min H, Danilenko DM, Scully SA, et al. Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev. 1998; 12: 3156-61.
15. Nakatake Y, Hoshikawa M, Asaki T, et al. Identification of a novel fibroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta. 2001; 1517: 460-3.
16. Beyer TA, Werner S, Dickson C, et al. Fibroblast growth factor 22 and its potential role during skin development and repair. Exp Cell Res. 2003; 287: 228-36.
17. Umemori H, Linhoff MW, Ornitz DM, et al. FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell. 2004; 118: 257-70.
18. Miki T, Fleming TP, Bottaro DP, et al. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science. 1991; 251: 72-5.
19. Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281: 15694-700.
20. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res. 2004; 91: 69-136.
21. Sekine K, Ohuchi H, Fujiwara M, et al. Fgf10 is essential for limb and lung formation. Nat Genet. 1999; 21: 138-41.
22. Guo L, Degenstein L, Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev. 1996; 10: 165-75.
23. Qiao J, Uzzo R, Obara-Ishihara T, et al. FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development. 1999; 126: 547-54.
24. Tash JA, David SG, Vaughan EE, et al. Fibroblast growth factor-7 regulates stratification of the bladder urothelium. J Urol. 2001; 166: 2536-41.
25. Adamson IY, Bakowska J. Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin. Am J Pathol. 1999; 155: 949-54.
26. Baskin LS, Sutherland RS, Thomson AA, et al. Growth factors in bladder wound healing. J Urol. 1997; 157: 2388-95.
27. Charafeddine L, D'Angio CT, Richards JL, et al. Hyperoxia increases keratinocyte growth factor mRNA expression in neonatal rabbit lung. Am J Physiol. 1999; 276: L105-13.
28. Estivariz CF, Gu LH, Scully S, et al. Regulation of keratinocyte growth factor (KGF) and KGF receptor mRNAs by nutrient intake and KGF administration in rat intestine. Dig Dis Sci. 2000; 45: 736-43.
29. Ichimura T, Finch PW, Zhang G, et al. Induction of FGF-7 after kidney damage: a possible paracrine mechanism for tubule repair. Am J Physiol. 1996; 271: F967-76.
30. Marchese C, Chedid M, Dirsch OR, et al. Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin. J Exp Med. 1995; 182: 1369-76.
31. Werner S, Peters KG, Longaker MT, et al. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci USA. 1992; 89: 6896-900.
32. Bajaj-Elliott M, Breese E, Poulsom R, et al. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts. Am J Pathol. 1997; 151: 1469-76.
33. Brauchle M, Madlener M, Wagner AD, et al. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol. 1996; 149: 521-9.
34. Finch PW, Murphy F, Cardinale I, et al. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol. 1997; 151: 1619-28.
35. Finch PW, Pricolo V, Wu A, et al. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology. 1996; 110: 441-51.
36. Braun S, Krampert M, Bodo E, et al. Keratinocyte growth factor protects epidermis and hair follicles from cell death induced by UV irradiation, chemotherapeutic or cytotoxic agents. J Cell Sci. 2006; 119: 4841-9.
37. Franco-Montoya ML, Bourbon JR, Durrmeyer X, et al. Pulmonary effects of keratinocyte growth factor in newborn rats exposed to hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2009; 297: L965-76.
38. Gomperts BN, Belperio JA, Fishbein MC, et al. Keratinocyte growth factor improves repair in the injured tracheal epithelium. Am J Respir Cell Mol Biol. 2007; 37: 48-56.
39. Gragnani A, Rossi MB, Albuquerque JC, et al. Keratinocyte growth factor protected cultured human keratinocytes exposed to oxidative stress. Acta Cir Bras. 2010; 25: 93-7.
40. Teranishi S, Kimura K, Kawamoto K, et al. Protection of human corneal epithelial cells from hypoxia-induced disruption of barrier function by keratinocyte growth factor. Invest Ophthalmol Vis Sci. 2008; 49: 2432-7.
41. Chen Y, Chou K, Fuchs E, et al. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci USA. 2002; 99: 14338-43.
42. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351: 2590-8.
43. Carstens RP, Wagner EJ, Garcia-Blanco MA. An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol. 2000; 20: 7388-400.
44. Wagner EJ, Garcia-Blanco MA. RNAi-mediated PTB depletion leads to enhanced exon definition. Mol Cell. 2002; 10: 943-9.
45. Luco RF, Pan Q, Tominaga K, et al. Regulation of alternative splicing by histone modifications. Science. 2010; 327: 996-1000.
46. Warzecha CC, Sato TK, Nabet B, et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009; 33: 591-601.
47. Warzecha CC, Shen S, Xing Y, et al. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol. 2009; 6: 546-62.
48. Warzecha CC, Jiang P, Amirikian K, et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010; 29: 3286-300.
49. Luo Y, Yang C, Jin C, et al. Novel phosphotyrosine targets of FGFR2IIIb signaling. Cell Signal. 2009; 21: 1370-8.
50. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 2008; 99: 1319-25.
51. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002; 283: E413-22.
52. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006; 6: 307-20.
53. Agazie YM, Movilla N, Ischenko I, et al. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 2003; 22: 6909-18.
54. Liang Q, Mohan RR, Chen L, et al. Signaling by HGF and KGF in corneal epithelial cells: Ras/MAP kinase and Jak-STAT pathways. Invest Ophthalmol Vis Sci. 1998; 39: 1329-38.
55. Lotti LV, Rotolo S, Francescangeli F, et al. AKT and MAPK signaling in KGF-treated and UVB-exposed human epidermal cells. J Cell Physiol. 2007; 212: 633-42.
56. Mehta PB, Robson CN, Neal DE, et al. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene. 2001; 20: 5359-65.
57. Taniguchi F, Harada T, Sakamoto Y, et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2003; 88: 773-80.
58. Uzan B, Figeac F, Portha B, et al. Mechanisms of KGF mediated signaling in pancreatic duct cell proliferation and differentiation. PLoS ONE. 2009; 4: e4734.
59. Zeigler ME, Chi Y, Schmidt T, et al. Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol. 1999; 180: 271-84.
60. Chang Y, Wang J, Lu X, et al. KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J Lipid Res. 2005; 46: 2624-35.
61. Bao S, Wang Y, Sweeney P, et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005; 288: L36-42.
62. Bartova I, Koca J, Otyepka M. Regulatory phosphorylation of cyclin-dependent kinase 2: insights from molecular dynamics simulations. J Mol Model. 2008; 14: 761-8.
63. Aoki N, Ueno S, Mano H, et al. Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. J Biol Chem. 2004; 279: 10765-75.
64. Gensler M, Buschbeck M, Ullrich A. Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. J Biol Chem. 2004; 279: 12110-6.
65. Dorner D, Vlcek S, Foeger N, et al. Lamina-associated polypeptide 2alpha regulates cell cycle progression and differentiation via the retinoblastoma-E2F pathway. J Cell Biol. 2006; 173: 83-93.
66. Naetar N, Korbei B, Kozlov S, et al. Loss of nucleoplasmic LAP2alpha-lamin A complexes causes erythroid and epidermal progenitor hyperproliferation. Nat Cell Biol. 2008; 10: 1341-8.
67. Fukuhara H, Masuda M, Yageta M, et al. Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene. 2003; 22: 6160-5.
68. Hanada N, Makino K, Koga H, et al. NE-dlg, a mammalian homolog of Drosophila dlg tumor suppressor, induces growth suppression and impairment of cell adhesion: possible involvement of down-regulation of beta-catenin by NE-dlg expression. Int J Cancer. 2000; 86: 480-8.
69. Ray P, Devaux Y, Stolz DB, et al. Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci U S A. 2003; 100: 6098-103.
70. Lu Y, Pan ZZ, Devaux Y, et al. p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte growth factor receptor and participates in keratinocyte growth factor-mediated inhibition of oxidant-induced cell death. J Biol Chem. 2003; 278: 10374-80.
71. Niu J, Chang Z, Peng B, et al. Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem. 2007; 282: 6001-11.
72. Koria P, Andreadis ST. KGF promotes integrin alpha5 expression through CCAAT/enhancer-binding protein-beta. Am J Physiol Cell Physiol. 2007; 293: C1020-31.
73. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol. 2002; 22: 5492-505.
74. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65: 7591-5.
75. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008; 105: 8713-7.
76. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001; 61: 3541-3.
77. Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007; 26: 7158-62.
78. Adnane J, Gaudray P, Dionne CA, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 1991; 6: 659-63.
79. Hattori Y, Odagiri H, Nakatani H, et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA. 1990; 87: 5983-7.
80. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res. 2004; 2: 643-52.
81. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447: 1087-93.
82. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, et al. Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res. 2007; 9: R78.
83. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007; 39: 870-4.
84. McGrath M, Lee IM, Buring J, et al. Novel breast cancer risk alleles and endometrial cancer risk. Int J Cancer. 2008; 123: 2961-4.
85. Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med. 2009; 23: 307-11.
86. Amann T, Bataille F, Spruss T, et al. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol. 2010; 176: 1433-42.
87. Carstens RP, Eaton JV, Krigman HR, et al. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene. 1997; 15: 3059-65.
88. Chaffer CL, Dopheide B, Savagner P, et al. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation. 2007; 75: 831-42.
89. Katoh M. Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol. 2005; 27: 1677-83.
90. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172: 973-81.
91. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54.
92. Feng S, Wang F, Matsubara A, et al. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 1997; 57: 5369-78.
93. Matsubara A, Kan M, Feng S, et al. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res. 1998; 58: 1509-14.
94. Ricol D, Cappellen D, El Marjou A, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene. 1999; 18: 7234-43.
95. Yasumoto H, Matsubara A, Mutaguchi K, et al. Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells. Prostate. 2004; 61: 236-42.
96. Zhang Y, Wang H, Toratani S, et al. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci U S A. 2001; 98: 11336-40.
97. Grose R, Fantl V, Werner S, et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007; 26: 1268-78.
98. Toriseva M, Ala-aho R, Peltonen S, et al. Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells. PLoS ONE. 2012; 7: e33041.
99. Jameson SC. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol. 2002; 2: 547-56.
100. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science. 2001; 294: 605-9.
101. Finch PW, Rubin JS. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst. 2006; 98: 812-24.
102. Bai A, Meetze K, Vo NY, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010; 70: 7630-9.
103. Chang HL, Sugimoto Y, Liu S, et al. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Anticancer Res. 2009; 29: 3195-205.
104. Chang HL, Sugimoto Y, Liu S, et al. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res. 2006; 26: 1773-84.
105. Hishikawa Y, Tamaru N, Ejima K, et al. Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol. 2004; 67: 455-64.
106. Rotolo S, Ceccarelli S, Romano F, et al. Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS ONE. 2008; 3: e2528.
107. Tamaru N, Hishikawa Y, Ejima K, et al. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest. 2004; 84: 1460-71.
108. Brake R, Starnes C, Lu J, et al. Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Mol Cancer Res. 2008; 6: 1337-46.
109. Hille A, Rave-Frank M, Pradier O, et al. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol. 2003; 79: 119-28.
110. Matsubara A, Teishima J, Mirkhat S, et al. Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells. Anticancer Res. 2008; 28: 2141-6.
111. Oelmann E, Haghgu S, Kulimova E, et al. Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol. 2004; 25: 1001-12.
112. Yu K, Xu J, Liu Z, et al. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development. 2003; 130: 3063-74.
113. Terauchi A, Johnson-Venkatesh EM, Toth AB, et al. Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature. 2010; 465: 783-7.
114. Lee CH, Javed D, Althaus AL, et al. Neurogenesis is enhanced and mossy fiber sprouting arises in FGF7-deficient mice during development. Mol Cell Neurosci. 2012; 51: 61-7.
115. O'Donovan MC, Norton N, Williams H, et al. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol Psychiatry. 2009; 14: 30-6.
116. Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998; 58: 933-9.
117. Farrell CL, Rex KL, Kaufman SA, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol. 1999; 75: 609-20.
118. Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys. 2002; 54: 245-51.
119. Borges L, Rex KL, Chen JN, et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. Int J Radiat Oncol Biol Phys. 2006; 66: 254-62.
120. Zheng C, Cotrim AP, Rowzee A, et al. Prevention of radiation-induced salivary hypofunction following hKGF gene delivery to murine submandibular glands. Clin Cancer Res. 2011; 17: 2842-51.
121. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008; 26: 3770-6.
122. Lombaert IM, Brunsting JF, Wierenga PK, et al. Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/progenitor pool. Stem Cells. 2008; 26: 2595-601.
123. Shafi MA, Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin North Am. 2010; 39: 629-47.
124. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer. 2005; 116: 464-70.
125. Byrne FR, Farrell CL, Aranda R, et al. rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2002; 282: G690-701.
126. Ulich TR, Whitcomb L, Tang W, et al. Keratinocyte growth factor ameliorates cyclophosphamide-induced ulcerative hemorrhagic cystitis. Cancer Res. 1997; 57: 472-5.
127. Jaal J, Dorr W. Effect of recombinant human keratinocyte growth factor (rHuKGF, Palifermin) on radiation-induced mouse urinary bladder dysfunction. Int J Radiat Oncol Biol Phys. 2007; 69: 528-33.
128. Boismenu R, Havran WL. Modulation of epithelial cell growth by intraepithelial gamma delta T cells. Science. 1994; 266: 1253-5.
129. Yang H, Antony PA, Wildhaber BE, et al. Intestinal intraepithelial lymphocyte gamma delta-T cell-derived keratinocyte growth factor modulates epithelial growth in the mouse. J Immunol. 2004; 172: 4151-8.
130. Housley RM, Morris CF, Boyle W, et al. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest. 1994; 94: 1764-77.
131. Johnson WF, DiPalma CR, Ziegler TR, et al. Keratinocyte growth factor enhances early gut adaptation in a rat model of short bowel syndrome. Vet Surg. 2000; 29: 17-27.
132. Otte JM, Boser S, Brunke G, et al. Expression of keratinocyte growth factor and its receptor in adaptive changes of ileorectal pouch mucosa. Scand J Gastroenterol. 2005; 40: 1066-75.
133. Salvati VM, Bajaj-Elliott M, Poulsom R, et al. Keratinocyte growth factor and coeliac disease. Gut. 2001; 49: 176-81.
134. Egger B, Procaccino F, Sarosi I, et al. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci. 1999; 44: 836-44.
135. Liu CJ, Jin JD, Lv TD, et al. Keratinocyte growth factor gene therapy ameliorates ulcerative colitis in rats. World J Gastroenterol. 2011; 17: 2632-40.
136. Estivariz CF, Jonal CR, Gu LH, et al. Gut-trophic effects of keratinocyte growth factor in rat small intestine and colon during enteral refeeding. JPEN J Parenter Enteral Nutr. 1998; 22: 259-67.
137. Cai Y, Wang W, Liang H, et al. Keratinocyte growth factor improves epithelial structure and function in a mouse model of intestinal ischemia/reperfusion. PLoS ONE. 2012; 7: e44772.
138. Yang H, Wildhaber BE, Teitelbaum DH. 2003 Harry M. Vars Research Award. Keratinocyte growth factor improves epithelial function after massive small bowel resection. JPEN J Parenter Enteral Nutr. 2003; 27: 198-206; discussion -7.
139. Goodlad RA, Mandir N, Meeran K, et al. Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration? Regul Pept. 2000; 87: 83-90.
140. Wildhaber BE, Yang H, Teitelbaum DH. Keratinocyte growth factor decreases total parenteral nutrition-induced apoptosis in mouse intestinal epithelium via Bcl-2. J Pediatr Surg. 2003; 38: 92-6; discussion -6.
141. Egger B, Tolmos J, Procaccino F, et al. Keratinocyte growth factor promotes healing of left-sided colon anastomoses. Am J Surg. 1998; 176: 18-24.
142. Jonas CR, Farrell CL, Scully S, et al. Enteral nutrition and keratinocyte growth factor regulate expression of glutathione-related enzyme messenger RNAs in rat intestine. JPEN J Parenter Enteral Nutr. 2000; 24: 67-75.
143. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140: 1807-16.
144. Sturlan S, Oberhuber G, Beinhauer BG, et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis. 2001; 22: 665-71.
145. Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology. 1997; 113: 1767-78.
146. Schalamon J, Mayr JM, Hollwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol. 2003; 17: 931-42.
147. Buchman AL, Moukarzel AA, Bhuta S, et al. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr. 1995; 19: 453-60.
148. Jonas CR, Estivariz CF, Jones DP, et al. Keratinocyte growth factor enhances glutathione redox state in rat intestinal mucosa during nutritional repletion. J Nutr. 1999; 129: 1278-84.
149. Cai YJ, Wang WS, Liang HY, et al. Keratinocyte growth factor up-regulates Interleukin-7 expression following intestinal ischemia/reperfusion in vitro and in vivo. Int J Clin Exp Pathol. 2012; 5: 569-80.
150. Johansson JE, Hasseus B, Johansson P, et al. Gut protection by palifermin during autologous haematopoietic SCT. Bone Marrow Transplant. 2009; 43: 807-11.
151. Washizawa N, Gu LH, Gu L, et al. Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats. JPEN J Parenter Enteral Nutr. 2004; 28: 399-409.
152. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991; 324: 667-74.
153. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000; 95: 2754-9.
154. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997; 64: 553-8.
155. MacDonald KP, Hill GR. Keratinocyte Growth Factor (KGF) in hematology and oncology. Curr Pharm Des. 2002; 8: 395-403.
156. Wirth K, Mertelsmann R. Cytoprotective function of keratinocyte growth factor in tumour therapy-induced tissue damage. Br J Haematol. 2002; 116: 505-10.
157. Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood. 1999; 94: 825-31.
158. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood. 2002; 99: 4592-600.
159. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, et al. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood. 1998; 92: 3960-7.
160. Vanclee A, Lutgens LC, Oving EB, et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant. 2005; 36: 907-15.
161. Alpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood. 2006; 107: 2453-60.
162. Ellison CA, Gibson IW, Hayglass KT, et al. Effect of palifermin in a murine model of graft-versus-host disease (GVHD) associated with Th2 cytokine production, autoantibody production, and glomerulonephritis. J Clin Immunol. 2006; 26: 485-94.
163. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood. 2000; 96: 4350-6.
164. Ellison CA, Natuik SA, Fischer JM, et al. Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without a preconditioning regimen. J Clin Immunol. 2004; 24: 197-211.
165. van Ewijk W, Wang B, Hollander G, et al. Thymic microenvironments, 3-D versus 2-D? Semin Immunol. 1999; 11: 57-64.
166. Revest JM, Suniara RK, Kerr K, et al. Development of the thymus requires signaling through the fibroblast growth factor receptor R2-IIIb. J Immunol. 2001; 167: 1954-61.
167. Erickson M, Morkowski S, Lehar S, et al. Regulation of thymic epithelium by keratinocyte growth factor. Blood. 2002; 100: 3269-78.
168. Jenkinson WE, Jenkinson EJ, Anderson G. Differential requirement for mesenchyme in the proliferation and maturation of thymic epithelial progenitors. J Exp Med. 2003; 198: 325-32.
169. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood. 2002; 100: 682-91.
170. Rossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood. 2007; 109: 3803-11.
171. Min D, Panoskaltsis-Mortari A, Kuro OM, et al. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood. 2007; 109: 2529-37.
172. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001; 97: 2983-90.
173. Zhang Y, Hexner E, Frank D, et al. CD4 + T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J Immunol. 2007; 179: 3305-14.
174. Seggewiss R, Lore K, Guenaga FJ, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood. 2007; 110: 441-9.
175. Cohen JL, Trenado A, Vasey D, et al. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002; 196: 401-6.
176. Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002; 196: 389-99.
177. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002; 99: 3493-9.
178. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, et al. L-Selectin(hi) but not the L-selectin(lo) CD4 + 25 + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004; 104: 3804-12.
179. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4 + CD25 + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003; 112: 1688-96.
180. Bruinsma M, van Soest PL, Leenen PJ, et al. Keratinocyte growth factor induces expansion of murine peripheral CD4 + Foxp3 + regulatory T cells and increases their thymic output. J Immunol. 2007; 179: 7424-30.
181. Bruinsma M, van Soest PL, Leenen PJ, et al. Keratinocyte growth factor improves allogeneic bone marrow engraftment through a CD4 + Foxp3 + regulatory T cell-dependent mechanism. J Immunol. 2009; 182: 7364-9.
182. Gudkov AV, Komarova EA. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun. 2005; 331: 726-36.
183. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285: 1733-7.
184. Kelly RM, Goren EM, Taylor PA, et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood. 2010; 115: 1088-97.
185. Kawashima I, Seiki K, Sakabe K, et al. Localization of estrogen receptors and estrogen receptor-mRNA in female mouse thymus. Thymus. 1992; 20: 115-21.
186. Kohen F, Abel L, Sharp A, et al. Estrogen-receptor expression and function in thymocytes in relation to gender and age. Dev Immunol. 1998; 5: 277-85.
187. Olsen NJ, Olson G, Viselli SM, et al. Androgen receptors in thymic epithelium modulate thymus size and thymocyte development. Endocrinology. 2001; 142: 1278-83.
188. Pearce PT, Khalid BA, Funder JW. Progesterone receptors in rat thymus. Endocrinology. 1983; 113: 1287-91.
189. Viselli SM, Olsen NJ, Shults K, et al. Immunochemical and flow cytometric analysis of androgen receptor expression in thymocytes. Mol Cell Endocrinol. 1995; 109: 19-26.
190. Goldberg GL, Alpdogan O, Muriglan SJ, et al. Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. J Immunol. 2007; 178: 7473-84.
191. Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation. 2005; 80: 1604-13.
192. Heng TS, Goldberg GL, Gray DH, et al. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005; 175: 2982-93.
193. Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004; 173: 6098-108.
194. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005; 175: 2741-53.
195. Kelly RM, Highfill SL, Panoskaltsis-Mortari A, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood. 2008; 111: 5734-44.
196. Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011; 118: 6438-45.
197. Wang Y, Chen G, Qiao S, et al. Keratinocyte growth factor enhanced immune reconstitution in murine allogeneic umbilical cord blood cell transplant. Leuk Lymphoma. 2011; 52: 1556-66.
198. Finch PW, Cunha GR, Rubin JS, et al. Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal-epithelial interactions. Dev Dyn. 1995; 203: 223-40.
199. Simonet WS, DeRose ML, Bucay N, et al. Pulmonary malformation in transgenic mice expressing human keratinocyte growth factor in the lung. Proc Natl Acad Sci U S A. 1995; 92: 12461-5.
200. Ulich TR, Yi ES, Longmuir K, et al. Keratinocyte growth factor is a growth factor for type II pneumocytes in vivo. J Clin Invest. 1994; 93: 1298-306.
201. Panos RJ, Bak PM, Simonet WS, et al. Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats. J Clin Invest. 1995; 96: 2026-33.
202. Guery BP, Mason CM, Dobard EP, et al. Keratinocyte growth factor increases transalveolar sodium reabsorption in normal and injured rat lungs. Am J Respir Crit Care Med. 1997; 155: 1777-84.
203. Savla U, Waters CM. Barrier function of airway epithelium: effects of radiation and protection by keratinocyte growth factor. Radiat Res. 1998; 150: 195-203.
204. Borok Z, Mihyu S, Fernandes VF, et al. KGF prevents hyperoxia-induced reduction of active ion transport in alveolar epithelial cells. Am J Physiol. 1999; 276: C1352-60.
205. Wang Y, Jayr C, Folkesson HG, et al. Alveolar epithelial fluid transport can be upregulated simultaneously in rats by two different mechanisms. Chest. 1999; 116: 98S-100S.
206. Viget NB, Guery BP, Ader F, et al. Keratinocyte growth factor protects against Pseudomonas aeruginosa-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L1199-209.
207. Welsh DA, Summer WR, Dobard EP, et al. Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model. Am J Respir Crit Care Med. 2000; 162: 1081-6.
208. Tillie-Leblond I, Gosset P, Le Berre R, et al. Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats. Eur Respir J. 2007; 30: 31-9.
209. LaFemina MJ, Rokkam D, Chandrasena A, et al. Keratinocyte growth factor enhances barrier function without altering claudin expression in primary alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2010; 299: L724-34.
210. Yano T, Mason RJ, Pan T, et al. KGF regulates pulmonary epithelial proliferation and surfactant protein gene expression in adult rat lung. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L1146-58.
211. Gesche J, Fehrenbach H, Koslowski R, et al. rhKGF stimulates lung surfactant production in neonatal rats in vivo. Pediatr Pulmonol. 2011; 46: 882-95.
212. Raith M, Schaal K, Koslowski R, et al. Effects of recombinant human keratinocyte growth factor on surfactant, plasma, and liver phospholipid homeostasis in hyperoxic neonatal rats. J Appl Physiol. 2012; 112: 1317-28.
213. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J. 2002; 20: 1449-56.
214. Matsumoto K, Nagayasu T, Hishikawa Y, et al. Keratinocyte growth factor accelerates compensatory growth in the remaining lung after trilobectomy in rats. J Thorac Cardiovasc Surg. 2009; 137: 1499-507.
215. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002; 282: L924-40.
216. Verghese GM, McCormick-Shannon K, Mason RJ, et al. Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance. Am J Respir Crit Care Med. 1998; 158: 386-94.
217. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA. 2009; 106: 16357-62.
218. Lindsay CD. Novel therapeutic strategies for acute lung injury induced by lung damaging agents: the potential role of growth factors as treatment options. Hum Exp Toxicol. 2011; 30: 701-24.
219. Barazzone C, Donati YR, Rochat AF, et al. Keratinocyte growth factor protects alveolar epithelium and endothelium from oxygen-induced injury in mice. Am J Pathol. 1999; 154: 1479-87.
220. Baba Y, Yazawa T, Kanegae Y, et al. Keratinocyte growth factor gene transduction ameliorates acute lung injury and mortality in mice. Hum Gene Ther. 2007; 18: 130-41.
221. Frank L. Protective effect of keratinocyte growth factor against lung abnormalities associated with hyperoxia in prematurely born rats. Biol Neonate. 2003; 83: 263-72.
222. Yano T, Deterding RR, Simonet WS, et al. Keratinocyte growth factor reduces lung damage due to acid instillation in rats. Am J Respir Cell Mol Biol. 1996; 15: 433-42.
223. Nemzek JA, Ebong SJ, Kim J, et al. Keratinocyte growth factor pretreatment is associated with decreased macrophage inflammatory protein-2alpha concentrations and reduced neutrophil recruitment in acid aspiration lung injury. Shock. 2002; 18: 501-6.
224. Ulrich K, Stern M, Goddard ME, et al. Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005; 288: L1179-92.
225. Wu H, Suzuki T, Carey B, et al. Keratinocyte growth factor augments pulmonary innate immunity through epithelium-driven, GM-CSF-dependent paracrine activation of alveolar macrophages. J Biol Chem. 2011; 286: 14932-40.
226. Stern JB, Fierobe L, Paugam C, et al. Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients. Crit Care Med. 2000; 28: 2326-33.
227. Quesnel C, Marchand-Adam S, Fabre A, et al. Regulation of hepatocyte growth factor secretion by fibroblasts in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 294: L334-43.
228. Chandel NS, Budinger GR, Mutlu GM, et al. Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways. Crit Care Med. 2009; 37: 1678-84.
229. McAuley D, Shyamsundar M, Calfee CS, et al. Kgf enhances the pulmonary production of epithelial repair factors following endotoxin induced lung inflammation and injury in human volunteers. Am J Respir Crit Care Med. 2011; 183: A2383.
230. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998; 26: 1793-800.
231. Browne G, Bhavsar M, O'Kane CM, et al. A potential role for keratinocyte growth factor and clarithromycin in the treatment of paraquat overdose. QJM. 2010; 103: 611-3.
232. Aguilar S, Scotton CJ, McNulty K, et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS ONE. 2009; 4: e8013.
233. Yi ES, Williams ST, Lee H, et al. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality. Am J Pathol. 1996; 149: 1963-70.
234. Guo J, Yi ES, Havill AM, et al. Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am J Physiol. 1998; 275: L800-5.
235. Sugahara K, Iyama K, Kuroda MJ, et al. Double intratracheal instillation of keratinocyte growth factor prevents bleomycin-induced lung fibrosis in rats. J Pathol. 1998; 186: 90-8.
236. Sakamoto S, Yazawa T, Baba Y, et al. Keratinocyte growth factor gene transduction ameliorates pulmonary fibrosis induced by bleomycin in mice. Am J Respir Cell Mol Biol. 2011; 45: 489-97.
237. Yi ES, Salgado M, Williams S, et al. Keratinocyte growth factor decreases pulmonary edema, transforming growth factor-beta and platelet-derived growth factor-BB expression, and alveolar type II cell loss in bleomycin-induced lung injury. Inflammation. 1998; 22: 315-25.
238. Deterding RR, Havill AM, Yano T, et al. Prevention of bleomycin-induced lung injury in rats by keratinocyte growth factor. Proc Assoc Am Physicians. 1997; 109: 254-68.
239. Chen L, Brizel DM, Rabbani ZN, et al. The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys. 2004; 60: 1520-9.
240. Liu CJ, Ha XQ, Jiang JJ, et al. Keratinocyte growth factor (KGF) gene therapy mediated by an attenuated form of Salmonella typhimurium ameliorates radiation induced pulmonary injury in rats. J Radiat Res. 2011; 52: 176-84.
241. Sadovski J, Kuchenbuch T, Ruppert C, et al. Keratinocyte growth factor prevents intra-alveolar oedema in experimental lung isografts. Eur Respir J. 2008; 31: 21-8.
242. Hirschburger M, Obert M, Traupe H, et al. Treatment with keratinocyte growth factor does not improve lung allograft survival in the rat. Langenbecks Arch Surg. 2009; 394: 133-41.
243. Kaza AK, Kron IL, Leuwerke SM, et al. Keratinocyte growth factor enhances post-pneumonectomy lung growth by alveolar proliferation. Circulation. 2002; 106: I120-4.
244. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011; 11: 36.
245. Plantier L, Marchand-Adam S, Antico Arciuch VG, et al. Keratinocyte growth factor protects against elastase-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L1230-9.
246. Yildirim AO, Veith M, Rausch T, et al. Keratinocyte growth factor protects against Clara cell injury induced by naphthalene. Eur Respir J. 2008; 32: 694-704.
247. Kovacs D, Falchi M, Cardinali G, et al. Immunohistochemical analysis of keratinocyte growth factor and fibroblast growth factor 10 expression in psoriasis. Exp Dermatol. 2005; 14: 130-7.
248. Staiano-Coico L, Krueger JG, Rubin JS, et al. Human keratinocyte growth factor effects in a porcine model of epidermal wound healing. J Exp Med. 1993; 178: 865-78.
249. Pierce GF, Yanagihara D, Klopchin K, et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med. 1994; 179: 831-40.
250. Danilenko DM, Ring BD, Tarpley JE, et al. Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor. Am J Pathol. 1995; 147: 1261-77.
251. Braddock M, Campbell CJ, Zuder D. Current therapies for wound healing: electrical stimulation, biological therapeutics, and the potential for gene therapy. Int J Dermatol. 1999; 38: 808-17.
252. Pierce GF, Mustoe TA. Pharmacologic enhancement of wound healing. Annu Rev Med. 1995; 46: 467-81.
253. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999; 7: 442-52.
254. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen. 1999; 7: 433-41.
255. Epstein SE, Fuchs S, Zhou YF, et al. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc Res. 2001; 49: 532-42.
256. Geer DJ, Swartz DD, Andreadis ST. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol. 2005; 167: 1575-86.
257. Waldeck H, Chung AS, Kao WJ. Interpenetrating polymer networks containing gelatin modified with PEGylated RGD and soluble KGF: synthesis, characterization, and application in in vivo critical dermal wound. J Biomed Mater Res A. 2007; 82: 861-71.
258. Ni Y, Turner D, Yates K, et al. Stabilization of growth factors relevant to wound healing by a plant cell wall biomaterial. Planta Med. 2007; 73: 1260-6.
259. Beer HD, Bittner M, Niklaus G, et al. The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene. 2005; 24: 5269-77.
260. Jeschke MG, Richter G, Hofstadter F, et al. Non-viral liposomal keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther. 2002; 9: 1065-74.
261. Pereira CT, Herndon DN, Rocker R, et al. Liposomal gene transfer of keratinocyte growth factor improves wound healing by altering growth factor and collagen expression. J Surg Res. 2007; 139: 222-8.
262. Drabick JJ, Glasspool-Malone J, King A, et al. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther. 2001; 3: 249-55.
263. Marti G, Ferguson M, Wang J, et al. Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Ther. 2004; 11: 1780-5.
264. Werner S, Smola H, Liao X, et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science. 1994; 266: 819-22.
265. Lin MP, Marti GP, Dieb R, et al. Delivery of plasmid DNA expression vector for keratinocyte growth factor-1 using electroporation to improve cutaneous wound healing in a septic rat model. Wound Repair Regen. 2006; 14: 618-24.
266. Escamez MJ, Carretero M, Garcia M, et al. Assessment of optimal virus-mediated growth factor gene delivery for human cutaneous wound healing enhancement. J Invest Dermatol. 2008; 128: 1565-75.
267. Kopp J, Wang GY, Kulmburg P, et al. Accelerated wound healing by in vivo application of keratinocytes overexpressing KGF. Mol Ther. 2004; 10: 86-96.
268. Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol. 2012; 30: 70-7.
269. Chamcheu JC, Siddiqui IA, Syed DN, et al. Keratin gene mutations in disorders of human skin and its appendages. Arch Biochem Biophys. 2011; 508: 123-37.
270. Sarkar R, Bansal S, Garg VK. Epidermolysis bullosa: where do we stand? Indian J Dermatol Venereol Leprol. 2011; 77: 431-8.
271. Tolar J, Blazar BR, Wagner JE. Concise review: transplantation of human hematopoietic cells for extracellular matrix protein deficiency in epidermolysis bullosa. Stem Cells. 2011; 29: 900-6.
272. Uitto J, McGrath JA, Rodeck U, et al. Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol. 2010; 130: 1778-84.
273. Bubier JA, Sproule TJ, Alley LM, et al. A mouse model of generalized non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol. 2010; 130: 1819-28.
274. Murat-Susic S, Husar K, Skerlev M, et al. Inherited epidermolysis bullosa - the spectrum of complications. Acta Dermatovenerol Croat. 2011; 19: 255-63.
275. Zhao H, Kegg H, Grady S, et al. Role of fibroblast growth factor receptors 1 and 2 in the ureteric bud. Dev Biol. 2004; 276: 403-15.
276. Yi ES, Shabaik AS, Lacey DL, et al. Keratinocyte growth factor causes proliferation of urothelium in vivo. J Urol. 1995; 154: 1566-70.
277. Vinsonneau C, Girshovich A, M'Rad MB, et al. Intrarenal urothelium proliferation: an unexpected early event following ischemic injury. Am J Physiol Renal Physiol. 2010; 299: F479-86.
278. Mutsaers SE. Mesothelial cells: their structure, function and role in serosal repair. Respirology. 2002; 7: 171-91.
279. Adamson IY, Bakowska J, Prieditis H. Proliferation of rat pleural mesothelial cells in response to hepatocyte and keratinocyte growth factors. Am J Respir Cell Mol Biol. 2000; 23: 345-9.
280. Adamson IY, Bakowska J. KGF and HGF are growth factors for mesothelial cells in pleural lavage fluid after intratracheal asbestos. Exp Lung Res. 2001; 27: 605-16.
281. Lopes JB, Dallan LA, Campana-Filho SP, et al. Keratinocyte growth factor: a new mesothelial targeted therapy to reduce postoperative pericardial adhesions. Eur J Cardiothorac Surg. 2009; 35: 313-8.
282. Lopes JB, Dallan LA, Moreira LF, et al. Synergism between keratinocyte growth factor and carboxymethyl chitosan reduces pericardial adhesions. Ann Thorac Surg. 2010; 90: 566-72.
283. Castagnino P, Lorenzi MV, Yeh J, et al. Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene. 2000; 19: 640-8.
284. Fassett JT, Nilsen-Hamilton M. Mrp3, a mitogen-regulated protein/proliferin gene expressed in wound healing and in hair follicles. Endocrinology. 2001; 142: 2129-37.
285. Gassmann MG, Werner S. Caveolin-1 and -2 expression is differentially regulated in cultured keratinocytes and within the regenerating epidermis of cutaneous wounds. Exp Cell Res. 2000; 258: 23-32.
286. Karvinen S, Pasonen-Seppanen S, Hyttinen JM, et al. Keratinocyte growth factor stimulates migration and hyaluronan synthesis in the epidermis by activation of keratinocyte hyaluronan synthases 2 and 3. J Biol Chem. 2003; 278: 49495-504.
287. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995; 270: 12607-13.
288. Beer HD, Munding C, Dubois N, et al. The estrogen-responsive B box protein: a novel regulator of keratinocyte differentiation. J Biol Chem. 2002; 277: 20740-9.
289. Pan ZZ, Devaux Y, Ray P. Ribosomal S6 kinase as a mediator of keratinocyte growth factor-induced activation of Akt in epithelial cells. Mol Biol Cell. 2004; 15: 3106-13.
290. Gassmann MG, Stanzel A, Werner S. Growth factor-regulated expression of enzymes involved in nucleotide biosynthesis: a novel mechanism of growth factor action. Oncogene. 1999; 18: 6667-76.
291. Braun S, Mauch C, Boukamp P, et al. Novel roles of NM23 proteins in skin homeostasis, repair and disease. Oncogene. 2007; 26: 532-42.
292. Putnins EE, Firth JD, Uitto VJ. Stimulation of collagenase (matrix metalloproteinase-1) synthesis in histiotypic epithelial cell culture by heparin is enhanced by keratinocyte growth factor. Matrix Biol. 1996; 15: 21-9.
293. Putnins EE, Firth JD, Uitto VJ. Keratinocyte growth factor stimulation of gelatinase (matrix metalloproteinase-9) and plasminogen activator in histiotypic epithelial cell culture. J Invest Dermatol. 1995; 104: 989-94.
294. Madlener M, Mauch C, Conca W, et al. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J. 1996; 320(Pt 2): 659-64.
295. Uitto VJ, Airola K, Vaalamo M, et al. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol. 1998; 152: 1489-99.
296. Tsuboi R, Sato C, Kurita Y, et al. Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. J Invest Dermatol. 1993; 101: 49-53.
297. Zheng J, Siren V, Vaheri A. Keratinocyte growth factor enhances urokinase-type plasminogen activator activity in HPV16 DNA-immortalized human uterine exocervical epithelial cells. Eur J Cell Biol. 1996; 69: 128-34.
298. Frank S, Werner S. The human homologue of the yeast CHL1 gene is a novel keratinocyte growth factor-regulated gene. J Biol Chem. 1996; 271: 24337-40.
299. Frank S, Munz B, Werner S. The human homologue of a bovine non-selenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene. Oncogene. 1997; 14: 915-21.